Search Results - "KEMPER, Kristel"

Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy by Kemper, Kristel, de Goeje, Pauline L, Peeper, Daniel S, van Amerongen, Renée

“…Mutations in BRAF are present in the majority of patients with melanoma, rendering these tumors sensitive to targeted therapy with BRAF and MEK inhibitors…”
Get full text

Monoclonal Antibodies Against Lgr5 Identify Human Colorectal Cancer Stem Cells by Kemper, Kristel, Prasetyanti, Pramudita R., De Lau, Wim, Rodermond, Hans, Clevers, Hans, Medema, Jan Paul

“…In colorectal cancer (CRC), a subpopulation of tumor cells, called cancer stem cell (CSC) fraction, is suggested to be responsible for tumor initiation,…”
Get full text

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma by Müller, Judith, Krijgsman, Oscar, Tsoi, Jennifer, Robert, Lidia, Hugo, Willy, Song, Chunying, Kong, Xiangju, Possik, Patricia A., Cornelissen-Steijger, Paulien D. M., Foppen, Marnix H Geukes, Kemper, Kristel, Goding, Colin R., McDermott, Ultan, Blank, Christian, Haanen, John, Graeber, Thomas G., Ribas, Antoni, Lo, Roger S., Peeper, Daniel S.

“…Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway…”
Get full text

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment by Merz, Christian, Medema, Jan Paul, Rodermond, Hans, Borovski, Tijana, Sprick, Martin R, Richel, Dick J, de Jong, Joan H, Todaro, Matilde, Cameron, Kate, De Sousa E Melo, Felipe, van der Heijden, Maartje, Vermeulen, Louis, Tuynman, Jurriaan B, Kemper, Kristel, Stassi, Giorgio

“…Cancer stem cell activity may not merely be an intrinsic characteristic of a subset of cancer cells and could be regulated by environmental cues. High Wnt…”
Get full text

Cancer drug addiction is relayed by an ERK2-dependent phenotype switch by Kong, Xiangjun, Kuilman, Thomas, Shahrabi, Aida, Boshuizen, Julia, Kemper, Kristel, Song, Ji-Ying, Niessen, Hans W. M., Rozeman, Elisa A., Geukes Foppen, Marnix H., Blank, Christian U., Peeper, Daniel S.

“…The identification of an ERK2–JUNB–FRA1 signalling pathway that drives addiction to therapeutic drugs in cancer cells, and an ERK2-dependent phenotype switch…”
Get full text

Molecular identification and targeting of colorectal cancer stem cells by Kemper, Kristel, Grandela, Catarina, Medema, Jan Paul

“…Tumor initiating or cancer stem cells (CSCs) are suggested to be responsible for tumor initiation and growth. Moreover, therapy resistance and minimal residual…”
Get full text

XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data by Kluin, Roelof J C, Kemper, Kristel, Kuilman, Thomas, de Ruiter, Julian R, Iyer, Vivek, Forment, Josep V, Cornelissen-Steijger, Paulien, de Rink, Iris, Ter Brugge, Petra, Song, Ji-Ying, Klarenbeek, Sjoerd, McDermott, Ultan, Jonkers, Jos, Velds, Arno, Adams, David J, Peeper, Daniel S, Krijgsman, Oscar

“…Mouse xenografts from (patient-derived) tumors (PDX) or tumor cell lines are widely used as models to study various biological and preclinical aspects of…”
Get full text

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma by Yu, Yong, Schleich, Kolja, Yue, Bin, Ji, Sujuan, Lohneis, Philipp, Kemper, Kristel, Silvis, Mark R., Qutob, Nouar, van Rooijen, Ellen, Werner-Klein, Melanie, Li, Lianjie, Dhawan, Dhriti, Meierjohann, Svenja, Reimann, Maurice, Elkahloun, Abdel, Treitschke, Steffi, Dörken, Bernd, Speck, Christian, Mallette, Frédérick A., Zon, Leonard I., Holmen, Sheri L., Peeper, Daniel S., Samuels, Yardena, Schmitt, Clemens A., Lee, Soyoung

“…Oncogene-induced senescence, e.g., in melanocytic nevi, terminates the expansion of pre-malignant cells via transcriptional silencing of proliferation-related…”
Get full text

Intra‐ and inter‐tumor heterogeneity in a vemurafenib‐resistant melanoma patient and derived xenografts by Kemper, Kristel, Krijgsman, Oscar, Cornelissen‐Steijger, Paulien, Shahrabi, Aida, Weeber, Fleur, Song, Ji‐Ying, Kuilman, Thomas, Vis, Daniel J, Wessels, Lodewyk F, Voest, Emile E, Schumacher, Ton NM, Blank, Christian U, Adams, David J, Haanen, John B, Peeper, Daniel S

“…The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical outcome of BRAF V600E metastatic melanoma. However, resistance to…”
Get full text

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors by Middelburg, Jim, Sluijter, Marjolein, Schaap, Gaby, Göynük, Büşra, Lloyd, Katy, Ovcinnikovs, Vitalijs, Zom, Gijs G., Marijnissen, Renoud J., Groeneveldt, Christianne, Griffioen, Lisa, Sandker, Gerwin G. W., Heskamp, Sandra, van der Burg, Sjoerd H., Arakelian, Tsolere, Ossendorp, Ferry, Arens, Ramon, Schuurman, Janine, Kemper, Kristel, van Hall, Thorbald

“…CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so…”
Get full text

Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities by Coppé, Jean-Philippe, Mori, Miki, Pan, Bo, Yau, Christina, Wolf, Denise M., Ruiz-Saenz, Ana, Brunen, Diede, Prahallad, Anirudh, Cornelissen-Steijger, Paulien, Kemper, Kristel, Posch, Christian, Wang, Changjun, Dreyer, Courtney A., Krijgsman, Oscar, Lee, Pei Rong Evelyn, Chen, Zhongzhong, Peeper, Daniel S., Moasser, Mark M., Bernards, René, van ‘t Veer, Laura J.

“…Phosphorylation networks intimately regulate mechanisms of response to therapies. Mapping the phospho-catalytic profile of kinases in cells or tissues remains…”
Get full text

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors by Azimi, Alireza, Caramuta, Stefano, Seashore‐Ludlow, Brinton, Boström, Johan, Robinson, Jonathan L, Edfors, Fredrik, Tuominen, Rainer, Kemper, Kristel, Krijgsman, Oscar, Peeper, Daniel S, Nielsen, Jens, Hansson, Johan, Egyhazi Brage, Suzanne, Altun, Mikael, Uhlen, Mathias, Maddalo, Gianluca

“…Novel therapies are undergoing clinical trials, for example, the Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for the treatment of…”
Get full text

Mutations in the Ras-Raf Axis Underlie the Prognostic Value of CD133 in Colorectal Cancer by KEMPER, Kristel, VERSLOOT, Miranda, MEDEMA, Jan Paul, CAMERON, Katherine, COLAK, Selçuk, DE SOUSA E MELO, Felipe, DE JONG, Joan H, BLEACKLEY, Joanne, VERMEULEN, Louis, VERSTEEG, Rogier, KOSTER, Jan

“…High expression of cancer stem cell (CSC) marker CD133 has been used as a predictor for prognosis in colorectal cancer (CRC), suggesting that enumeration of…”
Get full text

BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts by Kemper, Kristel, Krijgsman, Oscar, Kong, Xiangjun, Cornelissen-Steijger, Paulien, Shahrabi, Aida, Weeber, Fleur, van der Velden, Daphne L., Bleijerveld, Onno B., Kuilman, Thomas, Kluin, Roel J.C., Sun, Chong, Voest, Emile E., Ju, Young Seok, Schumacher, Ton N.M., Altelaar, A.F. Maarten, McDermott, Ultan, Adams, David J., Blank, Christian U., Haanen, John B., Peeper, Daniel S.

“…The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show promising results, but drug resistance often limits durable clinical…”
Get full text

Cyclooxygenase-2 Inhibition Inhibits c-Met Kinase Activity and Wnt Activity in Colon Cancer by TUYNMAN, Jurriaan B, VERMEULEN, Louis, BOON, Elles M, KEMPER, Kristel, ZWINDERMAN, Aeilko H, PEPPELENBOSCH, Maikel P, RICHEL, Dirk J

“…Activity of receptor tyrosine kinases (RTK) in colorectal cancer (CRC) is associated with enhanced tumor growth and a poorer prognosis. In addition,…”
Get full text

High-Throughput Assessment of Kinome-wide Activation States by Schmidlin, Thierry, Debets, Donna O, van Gelder, Charlotte A G H, Stecker, Kelly E, Rontogianni, Stamatia, van den Eshof, Bart L, Kemper, Kristel, Lips, Esther H, van den Biggelaar, Maartje, Peeper, Daniel S, Heck, Albert J R, Altelaar, Maarten

“…Aberrant kinase activity has been linked to a variety of disorders; however, methods to probe kinase activation states in cells have been lacking. Until now,…”
Get more information

813 Combination of HexaBody-CD27 with PD-(L)1 blockade potentiates single-agent activity leading to enhanced human T-cell effector functions in vitro by Imle, Andrea, Altintas, Isil, Nuermberger, Kristina, Blum, Jordan, Krause, Anna-Lena, Toker, Aras, Daszkiewicz, Lidia, Muik, Alexander, Gieseke, Friederike, Ahmadi, Tahamtan, Fellermeier-Kopf, Sina, Kemper, Kristel, Tuereci, Oezlem, Breij, Esther, Sahin, Ugur

“…BackgroundActivation of the T-cell co-stimulatory receptor CD27 and blockade of the PD-1:PD-L1 axis can augment antitumor immune responses through distinct…”
Get full text

889 DuoBody®-CD3x5T4 induces efficient T-cell activation and killing of patient-derived head and neck cancer cells in vitro and ex vivo by Ven, Rieneke van de, Ganzevles, Sonja, Veth, Myrthe, Franken, Patrick, Breij, Esther, Brakenhoff, Ruud, Kemper, Kristel

“…Background5T4, also known as trophoblast glycoprotein, is expressed in many solid cancers, including non-small cell lung cancer, triple-negative breast cancer,…”
Get full text

Parallel In Vivo and In Vitro Melanoma RNAi Dropout Screens Reveal Synthetic Lethality between Hypoxia and DNA Damage Response Inhibition by Possik, Patricia A., Müller, Judith, Gerlach, Carmen, Kenski, Juliana C.N., Huang, Xinyao, Shahrabi, Aida, Krijgsman, Oscar, Song, Ji-Ying, Smit, Marjon A., Gerritsen, Bram, Lieftink, Cor, Kemper, Kristel, Michaut, Magali, Beijersbergen, Roderick L., Wessels, Lodewyk, Schumacher, Ton N., Peeper, Daniel S.

“…To identify factors preferentially necessary for driving tumor expansion, we performed parallel in vitro and in vivo negative-selection short hairpin RNA…”
Get full text

704 Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models by Kemper, Kristel, Gielen, Ellis, Houtkamp, Mischa, Boross, Peter, Burm, Saskia, Poot, Stefanie De, Engelberts, Patrick, Goeij, Bart de, Satijn, David, Sasser, Kate, Breij, Esther

“…BackgroundThe tumor-associated antigen 5T4 is expressed across a wide range of solid cancers. DuoBody-CD3x5T4 is a bispecific antibody (bsAb) that crosslinks…”
Get full text